Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE 3: AZD6234 add-on to incretin-based therapy for obesity or overweight with comorbidities
MOH_2026-07-05_016918Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Lenbelintide add-on with Placebo add-on (2 arms). Started Jun 2026; status: recruiting.
02
Drugs
lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on MOH_2026-07-05_016918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-05_016918.